Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2013-002878-47-ES
EUCTR2013-002878-47-ES
Active, not recruiting
Not Applicable

A trial comparing sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensification - DUAL? - Intensification

ovo Nordisk A/S0 sites64 target enrollmentJanuary 16, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDiabetes Mellitus, Type 2MedDRA version: 16.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
DrugsNovoRapid

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 2
Sponsor
ovo Nordisk A/S
Enrollment
64
Status
Active, not recruiting
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 16, 2014
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Completion (Visit 28\) of NN9068\-3952 with insulin degludec/liraglutide \+ metformin.
  • •2\. HbA1c ? 7% at Visit 27 of NN9068\-3952 trial.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 51
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 13

Exclusion Criteria

  • •1\. Clinically significant diseases of the major organ systems.
  • •2\. Screening calcitonin ? 50ng/L.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A trial comparing sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensificatio
EUCTR2013-002878-47-HUovo Nordisk A/S64
Active, not recruiting
Not Applicable
A trial comparing sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensificatio
EUCTR2013-002878-47-SKovo Nordisk A/S64
Active, not recruiting
Not Applicable
A trial comparing sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensificatioDiabetes Mellitus, Type 2MedDRA version: 16.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2013-002878-47-GRovo Nordisk A/S64
Completed
Not Applicable
Evaluating the effect of a new supplement on recovery after open heart surgery
IRCT201312102480N3Shiraz University of Medical Sciences92
Recruiting
Not Applicable
Blood sugar control after bypass operation - insulin vs oral medicatioheart disease, diabetes
SLCTR/2014/024ational Hospital of Sri Lanka330